Palmitoyl Dipeptide-6

What is Palmitoyl Dipeptide-6?

'Palmitoyl Dipeptide-6' appears on ingredient lists mainly in the longer form Palmitoyl Dipeptide-6 Diaminohydroxybutyrate — one of the two synthetic, palmitic-acid-linked peptides in Syn-Tacks, a raw material from the Pentapharm/DSM 'Syn' peptide line (now dsm-firmenich). Older patent filings list Syn-Tacks as 'Glycerin, Palmitoyl Dipeptide-5 Diaminobutyloyl Hydroxythreonine, Palmitoyl Dipeptide-6 Diaminohydroxybutyrate'; the supplier and the EU CosIng inventory now name both components with 'Dipeptide-5', and there is no CosIng entry for a standalone 'Palmitoyl Dipeptide-6'. The companion peptide is Pal-Lys-Val-Dab-Thr (palmitoyl-lysyl-valyl-diaminobutyroyl-threonine), so Dipeptide-5 corresponds to Lys-Val. Older web descriptions of this ingredient as palmitoyl valine-tryptophan ('Pal-VW') are not supported by any authoritative source — Val-Trp is the INCI 'Dipeptide-2'. The supplier markets Syn-Tacks for the dermal-epidermal junction (DEJ), the layer that anchors the epidermis to the dermis, claiming it boosts hemidesmosomal and anchoring proteins for firmer, more elastic skin. Some retailers also describe it as 'retinol-like', but it has no retinoid activity and no published head-to-head data against retinoids. There is no peer-reviewed study of the ingredient on PubMed; all efficacy data are unpublished supplier claims.

What Palmitoyl Dipeptide-6 Is Investigated For

Palmitoyl Dipeptide-6 is a topical cosmetic peptide that reaches consumers almost entirely through the Syn-Tacks peptide complex. The supplier positions Syn-Tacks for the dermal-epidermal junction: it claims the peptide pair stimulates laminin V, collagens IV, VII and XVII and integrin β4 — the hemidesmosomal and basement-membrane proteins that hold the epidermis to the dermis — and that this improves elasticity, firmness and suppleness within weeks. None of this has been published in a peer-reviewed journal, and no study of the ingredient appears on PubMed. It shares the delivery strategy of the wider palmitoyl-peptide family (Matrixyl, Palmitoyl Tripeptide-1): a short peptide linked to palmitic acid to help it partition into the stratum corneum. Some retailers call it 'retinol-like', but that is marketing shorthand; it does not act on retinoic acid receptors and has never been compared with retinoids. Honest positioning: a plausible, gentle cosmetic active with a DEJ-focused rationale and no independent clinical evidence, used in multi-active anti-aging formulas.

How It Works

Palmitoyl Dipeptide-6 is a tiny skincare peptide attached to a fatty acid (palmitic acid) that helps it slip into the outer skin barrier. It is sold as part of a two-peptide complex (Syn-Tacks) that the supplier says strengthens the 'glue' layer between the outer skin and the dermis — the dermal-epidermal junction — by boosting the anchoring proteins there, which should make skin firmer and more elastic. It is sometimes called 'retinol-like', but it does not work like retinol, and the supplier's claims have not been tested in published studies.

Palmitoyl Dipeptide-6 Diaminohydroxybutyrate is a lipopeptide: a short peptide core extended with a diaminohydroxybutyric acid residue and capped at the N-terminus with palmitic acid, a C16 saturated fatty acid. It is supplied together with a second lipopeptide, Pal-Lys-Val-Dab-Thr (Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine), as the Syn-Tacks complex in glycerin; the current supplier and EU CosIng names give both components the 'Dipeptide-5' label. The palmitoyl modification is the design feature shared across the palmitoyl peptide family (Matrixyl, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7): a bare short peptide is hydrophilic and partitions poorly into the lipid-rich stratum corneum, whereas the lipidated version is amphipathic and penetrates the outer barrier more readily — though only a modest fraction of applied peptide typically reaches viable epidermis.\n\nThe supplier states that the Syn-Tacks peptide pair stimulates laminin V, collagens IV, VII and XVII, and integrin β4 — the proteins of the hemidesmosomes and basement membrane that anchor basal keratinocytes to the dermis and that decline with age — and that this restores dermal-epidermal junction function. These are unpublished manufacturer data; no peer-reviewed study has tested them. The specific receptor or primary target protein mediating any effect is not characterized. The 'retinol-like' description used by some retailers refers only to similar appearance-level goals; retinoids act through nuclear retinoic acid receptors, and this peptide has no known activity at that pathway.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Palmitoyl Dipeptide-6:

• 01No isolated-active human RCT — there is no published independent randomized controlled trial testing Palmitoyl Dipeptide-6 alone at a defined topical concentration against placebo with objective endpoints (wrinkle depth via profilometry, dermal density via ultrasound, firmness via cutometer).
• 02Mechanism specifics — the supplier's claim that the Syn-Tacks pair stimulates laminin V, collagens IV, VII and XVII and integrin β4 has never been published, and no receptor or target protein has been identified.
• 03Quantitative skin penetration — the fraction of applied Palmitoyl Dipeptide-6 reaching viable epidermis from typical cosmetic vehicles has not been published in independent literature.
• 04Head-to-head against retinoids — the 'retinol-like' marketing framing has never been rigorously tested against tretinoin, adapalene, tazarotene, or even cosmetic retinol in a comparative trial with standardized photoaging endpoints.
• 05Combination pharmacology within the palmitoyl-peptide family — whether stacking Palmitoyl Dipeptide-6 with Matrixyl or Palmitoyl Tripeptide-1 produces additive, redundant, or antagonistic effects is unstudied.
• 06Contribution of each component — Syn-Tacks contains two peptides, and no data separate the effect of Palmitoyl Dipeptide-6 from its Lys-Val companion.
• 07Durability after discontinuation — whether any cumulative effects of sustained use persist after cessation, or recede over weeks, has not been characterized.

Forms & Administration

Topical application in serums, creams, and anti-aging formulations, typically via the Syn-Tacks raw material (a glycerin solution of the two palmitoyl peptides, which retailers of the raw material list at a recommended use level of about 1% of the blend, not of pure peptide), as one ingredient among several cosmetic actives rather than as a stand-alone product. Frequently combined with other palmitoyl peptides (Matrixyl, Palmitoyl Tripeptide-1), copper peptides (GHK-Cu), neuropeptides (Argireline, SNAP-8), and established actives (retinoids, niacinamide, hyaluronic acid, vitamin C — usually applied at a different time of day to avoid pH-mediated destabilization). Skin penetration is the rate-limiting step for cosmetic peptides in general; vehicle and formulation affect real-world delivered dose more than nominal label concentration above a certain threshold. Not for injection — cosmetic peptide preparations are not sterile, are not formulated for parenteral use, and have no clinical rationale for injection.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions